We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
The Center for Medicare & Medicaid Services issued a long-awaited update to its online dashboard, increasing drug price transparency for consumers by adding year-over-year drug pricing changes and price-hiking manufacturers. “This time, you’ll actually be able to see the prices” for every drug in Medicaid and Medicare, said CMS Administrator Seema Verma at a healthcare forum hosted by The Washington Post. Read More
Clinical trial sponsors must step up their efforts to address underrepresentation of women among trial subjects, said FDA Commissioner Scott Gottlieb Wednesday during a meeting in White Oak, Maryland to commemorate National Women’s Health Week. Read More
West Virginia’s Supreme Court declined to expand the state’s product liability law to cover claims against branded drugs for harm caused by their generics. Read More
Gauging the 340B drug discount program’s effectiveness requires more price transparency and clearer guidance, expert witnesses told the Senate health committee Tuesday. Read More
In the latest development in the Michael Cohen-Novartis scandal, the U.S. Senate Committee on Finance pressured Novartis CEO Vasant Narasimhan for contracts and communications made between the pharma company and the president’s attorney. Read More